Trial Profile
Clinical study to investigate safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of inhaled multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with moderate to severe COPD – A randomised, double-blind, parallel group, multicenter, phase IIa pilot study – - SB010-COPD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Anti-GATA3 gene-therapy (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms SB010-COPD
- 19 Apr 2018 Results presented in a sterna biologicals Media Release.
- 19 Apr 2018 Results have been published in Respiratory Research.
- 11 Sep 2017 Results published in a Sterna biologicals Media Release.